RecruitingPhase 3NCT06456489
Pulse Steroid Injection in Refractory Rheumatoid Arthritis
Revealing the Potential of Intravenous Pulse Steroid Therapy; Impressive Results in Attaining Remission or Low Disease Activity in Refractory Rheumatoid Arthritis
Sponsor
Sohag University
Enrollment
268 participants
Start Date
May 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Remission or low disease activity in active rheumatoid arthritis
Eligibility
Min Age: 20 YearsMax Age: 65 Years
Inclusion Criteria1
- Refractory rheumatoid arthritis patients
Exclusion Criteria2
- Other connective tissue diseases
- Endocrine diseases such as DM and thyroid disorders
Interventions
DRUGSolumedrol
125 mg methylprednisolone intravenous pulse on 2 consecutive days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06456489